Regorafenib

Drug Profile

Regorafenib

Alternative Names: BAY-734506; DAST inhibitor - Bayer; fluoro-sorafenib; Stivarga

Latest Information Update: 30 Jan 2017

Price : $50

At a glance

  • Originator Bayer HealthCare
  • Developer Bayer HealthCare; British Columbia Cancer Agency; Memorial Sloan-Kettering Cancer Center; Spanish Cooperative Group for Digestive Tumour Therapy
  • Class Amides; Antineoplastics; Fluorobenzenes; Phenylurea compounds; Pyridines; Small molecules
  • Mechanism of Action Platelet-derived growth factor receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; TIE 2 receptor antagonists; Type 1 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastrointestinal stromal tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Gastrointestinal stromal tumours
  • Preregistration Hepatocellular carcinoma
  • Phase II Adenocarcinoma; Pancreatic cancer; Renal cell carcinoma; Solid tumours
  • Phase I Non-small cell lung cancer
  • Discontinued Wet age-related macular degeneration

Most Recent Events

  • 20 Jan 2017 Regorafenib receives priority review status for Hepatocellular carcinoma (Second-line therapy or greater) in Japan
  • 04 Jan 2017 Regorafenib receives priority review status for Hepatocellular carcinoma (Second-line therapy or greater)in USA
  • 07 Nov 2016 Preregistration for Hepatocellular carcinoma (Second-line therapy or greater) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top